Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Biophytis

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              FRANCE France

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Biophytis Announces a € 6.1 Million Capital Increase Through Private Placement

              Contact the Supplier

              Lead Product(s): Sarconeos

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO101

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: H.C. Wainwright & Co., LLC

              Deal Size: $6.8 million Upfront Cash: Undisclosed

              Deal Type: Private Placement July 03, 2020

              Details:

              Net proceeds of the private placement will be used primarily to progress Biophytis drug development programs, including the COVA clinical study, To begin Sarconeos (BIO101) Phase 2/3 clinical trial as a potential treatment for respiratory failure associated with COVID-19.

              PharmaCompass__DigitalAd